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sample t-test and one way ANOVA were used for statistical 
evaluation. 
 
Results: The median overall DBMFS was 12.9 months. A 
significant difference in median DBMFS was observed for 
patients with squamous cell vs. adenocarcinoma primary 
histology (4.57 months vs. 15.9 months, respectively, p 
<0.015). The initial number of metastases, total initial 
metastasis volume, ECD status, KPS scores, EGFR mutation 
status, or ALK gene rearrangement status, made no 
significant difference on DBMFS. None of the analyzed 
parameters displayed significant impact on ODBF. WBRT had 
no significant effect on DBMFS or ODBF in the study 
population, but patients with history of WBRT prior to SRS 
had an increased DBFR (0.396 vs. 0.089) which was borderline 
significant (p=0.05). There was an insufficient number of 
patients receiving combined WBRT with SRS to determine an 
effect on distant brain failure vs. SRS alone. 
 
Conclusion: Characterization of the risk of distant brain 
failure is important to treatment selection, prognosis and 
follow-up. Among lung cancer patients with brain metastases 
treated with SRS, our study found no impact from age, initial 
number/volume of metastases, EGFR/ALK status, or ECD 
status, on distant brain failure. However, this study did 
reveal a significantly shorter latency to appearance (DBMFS) 
of distant brain metastatic disease for patients with 
squamous vs. adenocarcinoma histology. The clinical 
prognostic significance of this histologic subtype-dependent 
difference on distant brain failure is the subject of further 
study. 
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Purpose or Objective: Most high-grade gliomas recur after 
initial multimodal therapy and re-irradiation has been shown 
to be a valuable re-treatment option in selected patients. We 
present the prognostic value of dynamic O-(2-18F-
fluoroethyl)-l-tyrosine ([18F]-FET) PET for patients treated 
with re-irradiation ± concomitant bevacizumab. Dynamic 
[18F]-FET-PET provides useful information to individualize 
treatment decisions and personalize risk stratification of 
patients with high-grade glioma recurrence. 
 
Material and Methods: We retrospectively analyzed 72 
patients suffering from recurrent high-grade glioma. Static 
and dynamic [18F]-FET-PET was performed prior to re-
irradiation. PET analysis revealed information about the 
maximal standardized uptake value (SUVmax) of the tumor 
corrected for the mean background (BG) (SUVmax/BG), the 
biologic tumor volume (BTV) and the mean tracer uptake 
within the BTV (SUVmean/BG). Dynamic parameters such as 
time-activity-curves (TACs) and minimal time-to-peak 
(TTPmin) were analyzed. Additional analysis was performed 
for gender, age, KPS, MGMT methylation status, IDH1 
mutational status, WHO grading, concomitant bevacizumab 
therapy and the number of foci. The influence of PET derived 
and clinical parameters on post-recurrence survival (PRS) was 
investigated. 
 
Results: TTPmin had a significant impact on PRS both on 
univariate (p=0.027) and multivariate analysis (p=0.008). 
Shorter TTPmin was related to shorter PRS after re-
irradiation with 6 months for TTPmin <12.5 min, 7 months for 
TTPmin 12.5 – 25 min and 11 months for TTPmin >25 min 
(p=0.027). Other factors significantly related to PRS were 
number of foci (p=0.025), TAC classifications (p=0.019; G1-2 
vs G3-5), and gender (p=0.028). 
Conclusion: Dynamic [18F]-FET-PET with TTPmin is of high 
prognostic value for recurrent high-grade glioma and might 
help to personalize re-irradiation treatment regimens in 
future either through PET-guided dose escalation or by 
combination therapy with targeted agents. 
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Purpose or Objective: The aim of this work is to investigate 
the pattern of failure for patients with glioblastoma, after 
FET-PET- and MRI-planned volumetric-modulated arc therapy 
(VMAT) with concomitant and adjuvant temozolomide (TMZ). 
Our hypothesis; FET-PET volume will better predict the 
pattern of failure and the inclusion of FET-PET in the 
radiation therapy target leads to a decrease in marginal 
failures. 
 
Material and Methods: We analysed the first 66 consecutive 
patients with histologically confirmed glioblastoma (WHO 
grade IV), scanned with FET-PET and MRI for post-surgical 
radiotherapy planning. Residual tumor volume including the 
resection cavity, denoted GTV(MR), was manually contoured 
on contrast-enhanced T1-weighted MRI (cT1). Metabolic 
tumor volume (GTV(PET)) was semi-automatically delineated 
by including tissue with uptake exceeding 1.6 times the 
uptake in normal appearing grey matter and subsequently 
edited to exclude non-tumor tissue. The CTV was created by 
adding a uniform margin of up to 2 cm to GTV(MR) and if 
necessary modified to include GTV(PET) and exclude natural 
boundaries such as the skull. A dose of 60 Gy was prescribed 
to the PTV (CTV plus 0.2 cm) in 2 Gy fractions, five days a 
week, using VMAT. TMZ was administered daily with 
radiotherapy (75 mg/m2) and subsequently in 6 cycles in a 5 
days schedule every 28 days (150-200 mg/m2). The 
recurrence volume (RV) was evaluated radiologically on 
follow-up cT1 according to the RANO-criteria. Patterns of 
failure were classified as central, in-field or marginal if >95%, 
80-95% or 20-80% of the RV was located within the 95% 
isodose (D95%). In case of the appearance of any new lesion 
outside the D95% or if <20% of the RV was within D95%, the 
failure was defined as distant. The treatment failure overlap 
(TFO) for three pre-treatment tumor volumes; GTV(MR), 
GTV(PET) and the union of the two, denoted GTV(MRPET), 
were calculated as the intersection of each GTV and RV 
divided by RV. Differences were assessed using Willcoxon 
signed rank test. 
 
Results: Sixteen patients were excluded due to; no follow-up 
imaging (n=6), incomplete RT (n=3), whole-brain irradiation 
(n=1), clinical deterioration but no sign of radiological 
progression (n=2) and four patients were progression-free at 
the time of analysis (median follow-up 38.5 months). All 
patients were FET-positive. The pattern of failure was 
central, in-field, marginal and distant in 82%, 10%, 2% and 
6%, respectively. The TFO were in median 0.73, 0.34 and 
0.87 for GTV(MR), GTV(PET) and GTV(MRPET), respectively. 
All TFO were significantly different (p<0.001). 
 
Conclusion: The inclusion of FET in radiotherapy planning 
leads to fewer marginal failures compared to previously 
reported studies. FET-PET alone is not better than MRI to 
predict the pattern of failure in glioblastoma patients. 
However, the combination of the two appears better than 
either of the modalities alone. 
 
 
